Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial

Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial

Introduction Psoriatic arthritis (PsA) is a complex, immune-mediated disease associated with skin psoriasis that, if left untreated, can lead to joint destruction. Up to 30% of patients with psoriasis progress to PsA. In most cases, psoriasis precedes synovio-entheseal inflammation by an average of...

Full description

Bibliographic Details
Main Authors: Joseph F Merola, Lihi Eder, Proton Rahman, Soumya D Chakravarty, Jose U Scher, Alexis Ogdie, Rebecca B Blank, Vincent Piguet, C T Ritchlin, Jonathan Samuels, Kun Qian, Wayne Gulliver, Ralf G Thiele, Rebecca H Haberman, Rochelle Castillo, Cinty Gong, Andrea L Neimann, Katrina A MacFarlane, Sydney Catron, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Francisco Tausk, Jensen Yeung
Format: Article
Language:English
Published: BMJ Publishing Group 2022-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/12/e063650.full

Internet

https://bmjopen.bmj.com/content/12/12/e063650.full

Similar Items